

Impact of Vitamin D Elements and Osteoporosis Factors in Postmenopausal Iraqi Women with T2DM

¹Howraa R. Alkabi*, ¹Wafaa R. Alfatlawi, ²Muhammed A. H. Aldabagh

¹Department of Applied Sciences, University of Technology – Iraq

²Medical Research Unit, College of Medicine, Al-Nahrain University – Iraq

Article information

Article history:

Received: December, 01, 2021

Accepted: August, 10, 2022

Available online: September, 10, 2022

Keywords:

Bone mineral density,
Diabetes,
Osteocalcin

*Corresponding Author:

Hawraa Raheem alkabi

as.19.05@grad.uotechnology.edu.iq

Abstract

Osteoporosis is a systematic bone disorder characterized by bone mass loss and bone tissue architectural degeneration. The incidence of osteoporosis in women increases with age, reflecting the considerable increase in bone loss rate in postmenopausal women once estrogen loses its protective influence. The purpose of this study was to determine the levels of Osteocalcin, Vitamin D, and other parameters that influence bone quality and increased bone fragility in postmenopausal Iraqi women with type 2 diabetes mellitus (T2DM). The levels of vitamin D receptor and vitamin D binding protein in serum are studied for the first time in our study. The present study included 89 postmenopausal women aged 50-70 years old, 62 T2DM patients, and 27 controls. Ten of the T2DM patients were considered osteoporotic, 28 were considered osteopenia, and 22 were normal; this classification is according to the WHO criterion. After matching for body mass index (BMI) and age for patients and controls, results show a significant difference in serum Osteocalcin, vitamin D, and vitamin D binding protein levels in patients compared to controls. In our study, diabetic patients appear with high levels of Osteocalcin, vit.D, and vitamin D binding protein compared with non-diabetic control. The processes underlying diabetes mellitus-induced skeletal problems are unknown. Anti-diabetic medications might have an adverse or favorable effect on bone metabolism. The study concludes that managing skeletal health in postmenopausal women entails screening fracture risk factors, lowering modifiable risk variables through dietary and lifestyle modifications, and using a pharmacologic treatment for individuals at high risk of osteoporosis or fracture. Women with osteoporosis must be managed for the rest of their lives.

DOI: [10.53293/jasn.2022.4483.1114](https://doi.org/10.53293/jasn.2022.4483.1114), Department of Applied Sciences, University of Technology
This is an open access article under the CC BY 4.0 License.

1. Introduction

Osteoporosis (OP) and diabetes mellitus (DM) are two of the most frequent diseases [1]. OP is the asymptomatic decrease of bone mass that is most common in postmenopausal women; over 40% of these women will have an osteoporosis-related fracture at some point in their lives[2]. Diabetes mellitus (DM) is a chronic metabolic

condition that mostly affects adults and is linked to a high rate of morbidity and death [3]. Type 2 diabetes is caused by insulin resistance, a disease in which cells fail to utilize insulin efficiently, and insufficient insulin production, often associated with absolute insulin deficiency [4-7]. Individuals with T2DM, particularly those on hypoglycemic drugs and those with comorbidities such as neuropathy and retinopathy, are more prone to fall, leaving them more vulnerable to fractures. An increased incidence of fractures is also linked to hyperparathyroidism and renal osteodystrophy. [8]. In addition to the standard method of bone densitometry, various biochemical bone metabolism biomarkers are utilized to diagnosis of osteoporosis [9]. One of those markers is Osteocalcin, also known as bone Gla protein, a marker for bone development. It induces insulin synthesis and enhances energy consumption and insulin sensitivity in target organs as a hormone. Increased circulation levels of Osteocalcin, especially by exogenous protein consumption, have been demonstrated in animal experiments to prevent obesity and glucose intolerance. Some epidemiological studies back up osteocalcin's involvement in maintaining human glucose and energy balance [10]. Monitoring Osteocalcin levels might help determine how well patients respond to therapy for metabolic bone disorders or anticipate a bone loss in postmenopausal women [10, 11]. Vit D insufficiency and T2DM share many risk factors, including African Americans, Asians, and Latinos, increasing obesity, advanced age, and a lack of physical activity (which may lead to less outdoor time or exposure to sunlight), which may not be a coincidence [12]. Furthermore, Vitamin D promotes bone health and helps to avoid osteoporosis and fractures. Vit D deficiency and inadequate dietary vitamin D are frequent in older people and are linked to an increasingly higher risk of fractures [13]. For most people, the synthesis of Vit D in the skin after exposure to UV-B radiation [290-315nm] is the main source of Vit D, which converts 7-dehydrocholesterol to provitamin D₃. The molecule is pushed into the extracellular space and drawn to the capillary bed, where it binds to Vit D binding protein (DBP) and is delivered to the liver due to these structural modifications [14]. Then, vitamin D₃ is converted into 25-hydroxycholecalciferol (25OHD) by 25-hydroxylase (CYP2R1). This process mainly occurs in the liver, The final stage of the formation of active 1,25-dihydroxycholecalciferol (1,25 (OH)₂ D) is mediated by the enzyme 25-hydroxyvitamin D₁α-hydroxylase (CYP27B1), which is found in proximal tubular cells[15], the active form 1,25(OH)₂ D₃ enter the cells and bind to Vit D receptor (VDR) and react with the Vit D response elements[16, 17]. Vit D binding protein (DBP) is a multifunctional protein with a molecular weight of (52–59) kDa that has been well preserved during the evolution of vertebrates and is mainly produced in the liver [18]. Vit D receptor is required for most of vitamin D's actions, with 1,25 (OH)₂ D as the primary ligand. Vit D receptor is considered a transcription factor. Intestinal epithelial cells, osteoblasts, parathyroid cells, and distal renal tubules express VDR, which is important in calcium and phosphate balance [19, 20]. Some researchers have looked at the link between obesity and lifestyle behaviors and osteoporosis and osteopenia, finding that a lower BMI and smoking were positively linked with osteoporosis or osteopenia in the general population and the T2DM group [21]. Discoveries on the multiple functions of Vit D include the presence of VDR in pancreatic β-cells, and the expression of 1α -hydroxylase in pancreatic β-cells, which is responsible for the conversion of 25(OH)D to (1,25(OH)₂D). Vit D response elements are found in the human insulin gene promoter, and VDR is found in skeletal muscle. Furthermore, 1,25(OH)₂D directly activates human insulin receptor gene transcription, activates the peroxisome activator of δ-receptor proliferators, increases insulin receptor expression, and enhances insulin-mediated glucose transport [22]. Vitamin D insufficiency is linked to insufficient bone mass or insufficient bone remodeling, which can lead to bone fragility and an increased risk of fractures, since vitamin D regulates the interaction between osteoblasts, osteoclasts, and osteocytes [23]. Bone density decreases by around 10% on average during the menopausal transition phase [24].

2. Subjects and Methods

The current case-control study included 89 postmenopausal women aged 50-70 old, 62 of them are T2DM patients and 27 control. The study was conducted during the period from November 2020 to March 2021. A total of 89 postmenopausal women aged 50-70 years old participated in the study. They were recruited from the medical City of Baghdad Teaching Hospital, educational laboratory, and Kadhimiya Teaching Hospital. Among the postmenopausal women, 62 were T2DM patients, and 27 were controls. According to the WHO criterion, ten of the T2DM patients were considered osteoporotic: T-score less than -2.5 below the normal adult mean based on the established reference databases. And 28 of the patients were considered osteopenia as their T-score was between -2.5 and -1. And 22 patients who were T-score more than -1 were normal. Exclusion criteria included subjects who received osteoporosis therapy and Vit D. By measuring bone mineral density (BMD) with dual-energy x-ray absorptiometry (DXA), patients were diagnosed with osteoporosis and controls were diagnosed as normal, according to World Health Organization (WHO) diagnostic guidelines: •A T-score of -1.0 or above is considered

"normal." •Osteopenia is defined as a T-score of -1.0 to -2.5. •Osteoporosis is defined as a T-score of -2.5 or below. Serum FBS and lipid profile measured by spectrophotometer, serum Osteocalcin, Vit D, VDR and DBP measured by enzyme-linked immune sorbent assay (ELISA) using kits manufactured by Sunlong /China. BMI was measured for patients and control. The mean and standard deviation were used to analyze the data. The significance of difference was determined using the Student-t-test for two independent means.

3. Results and Discussion

Sixty-eight T2DM patients (postmenopausal women) and 27 control were included in this study, the results showed in Tables 1-7 and Figures 1-8, the mean age for the patients and control groups was (61.58±5.08), (56.66±5.56) respectively. The results also showed a significant difference in FBS between patients and control. Our results showed a non-significant difference in m±sd of BMI between patients and control groups, but both groups were classified as obese.

Table 1: Age and body mass index of patients and control groups.

Marker	Control	Patients	P value (sig<0.05)
Age	56.66±5.56	61.58±5.08	≤0.001
BMI	30.66±7.24	31.77±6.86	0.494

Table 2: Fasting blood sugar and vitamin D levels in patients and control groups.

Marker	Control	Patients	P value (sig<0.05)
FBS (mg/dl)	92.29 ± 17.79	178.96±83.4	≤0.001
Vit D (ng/ml)	21.23±2.55	24.29±2.82	≤0.001




Figure 1: body mass index in patients and control groups.




Figure 2: Levels of vitamin D in patients and control groups.




Figure 3: Levels of fasting blood sugar in patients and control group.

In this study, the difference in $m \pm sd$ of Vit D was significant between patients and control, Vit D level was lower than the normal range (≥ 30 ng/dl) in both patients and control, but it was surprisingly lower in patients than control, these results agreed with Alhumaidi et al. who studied vitamin D deficiency in T2DM, and the results showed a low 25OHD level in patients and a lower level in control [25, 26]. Another cross-sectional study was done by Hidayat *et al.* [27], who evaluated the association between Vit D and t2dm in elderly subjects, the result revealed 78% Vit D deficiency in both patients and control, and explained this results by suggesting that variables like BMI, use of sun protection and sex had a substantial impact on the occurrence of Vit D deficiency. Women with menopause have thinner skin and a lower capacity for vitamin D production, and decreased vitamin D absorption in the intestine and hydroxylation of vitamin D in the liver and kidneys. These metabolic abnormalities will be accompanied by decrease outdoor activity and a lower vitamin D consumption in the diet [28, 29]. Some research has suggested that vitamin D may have a direct (through its function in pancreatic beta-cell activation and sensitive organs) or indirect (by calcium homeostasis control) favorable influence on insulin secretion and sensitivity [30]. Osteoporosis is a well-known fact among postmenopausal women, and several risk factors have been linked to this high prevalence, including vitamin, D deficiency [31]. The National, Health and Nutrition, Examination, Survey III (NHANES III) found a link between 25(OH) D and BMD in 13,432 participants, including whites, Hispanics, and blacks [32].

Table 3: Levels of vitamin D receptor and vitamin D binding protein.

Marker	Control	patients	P value (sig \leq 0.05)
VDR (ng/ml)	0.86 \pm 0.31	1.05 \pm 0.32	0.012
DBP (ug/ml)	0.27 \pm 0.12	0.44 \pm 0.13	\leq 0.001




Figure 4: Vitamin D binding protein levels in patients and control groups.

The total 25(OH) D, which comprises DBP and albumin-bound 25(OH)D and the free form, is measured in the serum. Because the most of 25(OH) D is bound to DBP, the overall 25(OH) D concentration will be influenced by the serum DBP concentration. DBP levels remain relatively constant throughout life. However, they arise during pregnancy and estrogen supplementation. Low serum DBP levels can also be caused by protein loss in the urine

(as seen in some diabetic patients) [33]. This was consistent with our results which revealed a significant difference in Vit D and DBP between patients and control. The results of our study showed a non-significant difference in the serum level of VDR between patients and control groups. Vitamin D receptor is found in renal tubules, intestinal epithelial cells, parathyroid gland cells, skin (keratinocytes), pancreas (beta islet cells), pituitary gland, skeleton (osteoblasts and chondrocytes), mammary epithelial cells, germ tissues and immune system (monocytes, macrophages, and T-lymphocytes) [34].




Figure 5: Levels of Vitamin D receptor in patients and control groups.

Vitamin D receptors may be playing an essential role in maintaining the maturity of β -cells which prevent them from undergoing dedifferentiation [35]. The VDR's presence in bone cells shows that it directly affects bone. These receptors are found in osteoblasts as well as immature osteoclast precursor cells. It was previously thought that the active vitamin D metabolites' action on osteoclasts was indirect via osteoblasts [36]. Our study showed a non-significant difference in BMD between patients and control. These results agreed with Han et, al. [37] and Anaforoglu et, al. [38], while Raska et al. [39] disagree with these results they found that BMD in T2DM patients was higher than non-diabetic control.

Table 4: Measurements of spine bone mineral density and T.score.

Marker	Control	Patients	P value (sig \leq 0.05)
Spine T.score	-0.73 \pm 1.41	-1.0 \pm 1.31	0.39
Spine BMD g/cm ²	0.97 \pm 0.15	0.94 \pm 0.18	0.46




Figure 6: Spine bone mineral density for patients and control groups.

According to some data, type 2 DM patients may have normal or enhanced BMD [40-42]. Several studies have found additional benefits of metformin therapy, such as improved bone quality in diabetics and reduced fracture risk [43]. Metformin reduces hepatic glucose synthesis by blocking major gluconeogenesis enzymes and improves peripheral insulin sensitivity. Experiments have shown that it positively affects bone growth[44]. The Previous study has revealed that osteoclasts produced from the bone marrow enhance bone destruction in the

postmenopausal age when estrogen levels decline. Due to the mutually reinforcing nature of bone degradation and synthesis, an increase in bone breakdown also stimulates bone synthesis, resulting in a high rate of bone turnover [45]. Postmenopausal T2DM patients have the exact opposite problem. Unlike T1DM patients and osteoporotic postmenopausal women, T2DM patients experience slower bone loss. Data showing a reduction in bone turnover were discovered when biomarkers of bone turnover were investigated, particularly in well-controlled diabetes persons. This furthermore explains the existing phenomenon in T2DM patients of delayed bone loss [46, 47]. In a study of T2DM patients, Wakasugi and colleagues [48, 49] found that a substantial decline in BMD occurred only after the twentieth year of the illness, demonstrating the delayed bone loss pattern reported in T2DM patients.

Table 5: Level of serum osteocalcin in patients and control groups.

Marker	Control	Patients	P value (sig≤0.05)
Osteocalcin (ng/ml)	5.44±1.12	9.09±6.5	≤0.001




Figure 7: Levels of osteocalcin in patients and control groups.

Osteocalcin is produced during the formation of bones. It has a compact, calcium-dependent alpha-helical shape in which the Gamma Carboxyglutamic Acid (GLA) residues bind to hydroxyapatite in the bone matrix and facilitate absorption. Bone mineralization occurs in this manner. In osteoporotic women, calcium and phosphorus deficits reduce the development of hydroxyapatite crystals, allowing free Osteocalcin to circulate in the bloodstream. This could explain why Osteocalcin levels in the serum of osteoporotic postmenopausal women are higher [50]. This was agreed with the results of this study which revealed that serum Osteocalcin level in T2DM patients was significantly higher than in control.

Table 6: HDL, LDL, and VLDL levels in patients and control groups.

Marker	Control	Patients	P value (sig≤0.05)
HDL (mg/dl)	48.54±12.07	43.43±8.58	0.05
LDL (mg/dl)	114.19±13.25	113.76±40.46	0.94
VLDL (mg/dl)	39.51±13.34	30.96±9.14	0.004

Table 7: Total cholesterol and triglyceride levels in patients and control groups.

Marker	Control	Patients	P value (sig≤0.05)
TC (mg/dl)	186.34±40.02	179.95±51.08	0.57
TG (mg/dl)	157.93±95.62	163.61±92.23	0.79

In this study, there was a significant decrease in serum HDL-C in T2DM patients when compared with non-diabetic healthy control and this is in accordance with the study of Al-Tu'ma et al. [51]. Because androgen and estrogen receptors are present in visceral and subcutaneous adipocytes, endogenous sex hormones have altered the lipid profile in postmenopausal women. As a result, changes in endogenous sex hormone concentrations in middle-aged women's adipose tissues may disrupt lipid metabolism [52].




Figure 8: Levels of high-density lipoprotein in patients and control groups.

4. Conclusions

The current study's findings suggest that high LDL and low HDL levels may be linked to the development of osteoporosis in postmenopausal women. There is no significant difference in vitamin D levels between patients and control. In this study, bone mineral density was not affected by T2DM, and there are no differences in the prevalence of osteoporosis between diabetic and non-diabetic subjects.

Conflict of Interest

The authors declare that they have no conflict of interest.

References

- [1] S. Ferrari, R. Eastell, N. Napoli, A. Schwartz, L. C. Hofbauer, A. Chines, *et al.*, "Denosumab in postmenopausal women with osteoporosis and diabetes: Subgroup analysis of FREEDOM and FREEDOM extension," *Bone*, vol. 134, p. 115268, 2020.
- [2] M. Sinaki, "Osteoporosis," in *Braddom's Physical Medicine and Rehabilitation*, ed: Elsevier, 2021, pp. 690-714. e3.
- [3] Q. Zou, K. Qu, Y. Luo, D. Yin, Y. Ju, and H. Tang, "Predicting Diabetes Mellitus With Machine Learning Techniques," *Frontiers in Genetics*, vol. 9, p. 515, 2018.
- [4] A. M. AL-Gebori, S. S. Adeeb, G. H. Alwan, H. R. Obayes, R. T. Rasheed, N. Al Derzi, *et al.*, "Correlation of Total Cholesterol and Glucose in Serum of Iraqi Patients with Atherosclerosis and Diabetes Mellitus Type 2," *Engineering and Technology Journal*, vol. 31, pp. 801-801, 2013.
- [5] i. m. maison khalifa, "Evaluation of Diabetes Treatment Methods And Effect of Their Complications on Kidney," *Engineering and Technology Journal*, vol. 28, pp. 907-922, 2010.
- [6] Z. M. ALI, W. R. ALFATLAWI, and M. A.-G. ALDABAGH, "Role of insulin dysfunction in development of dyslipidemia in type 2 diabetes mellitus (DM2)," *International Journal of Pharmaceutical Research*, vol. 12, p. 3745, 2020.
- [7] A. R. Rasheed, W. Ragee, and Q. S. Al-mayah, "ASSOCIATION OF PROGRAMMED CELL DEATH PROTEIN-1 (PD-1) GENE POLYMORPHISM AND SERUM LEVELS OF SOLUBLE PD-1 WITH TYPE 2 DIABETES MELLITUS," *Annals of Tropical Medicine and Public Health*, vol. 23, pp. 187-195, 2020.
- [8] A.-K. Picke, G. Campbell, N. Napoli, L. C. Hofbauer, and M. Rauner, "Update on the impact of type 2 diabetes mellitus on bone metabolism and material properties," *Endocrine connections*, vol. 8, pp. R55-R70, 2019.
- [9] X. Cheng, H. Yuan, J. Cheng, X. Weng, H. Xu, J. Gao, *et al.*, "Chinese expert consensus on the diagnosis of osteoporosis by imaging and bone mineral density," *Quantitative Imaging in Medicine and Surgery*, vol. 10, p. 2066, 2020.

- [10] A. Mizokami, T. Kawakubo-Yasukochi, and M. Hirata, "Osteocalcin and its endocrine functions," *Biochemical pharmacology*, vol. 132, pp. 1-8, 2017.
- [11] N. S. Ahmed, Y. A. Hadi, W. R. Alfatlawi, and G. S. Nsaif, "Relationship between Breast cancer and Vitamin A and Family history of Iraq women population," *Research Journal of Biotechnology* vol. 14, pp. 259-261, 2019.
- [12] S. Saintonge, H. Bang, and L. M. Gerber, "Implications of a new definition of vitamin D deficiency in a multiracial us adolescent population: the National Health and Nutrition Examination Survey III," *Pediatrics*, vol. 123, pp. 797-803, 2009.
- [13] P. H. Anderson, "Vitamin D activity and metabolism in bone," *Current Osteoporosis Reports*, vol. 15, pp. 443-449, 2017.
- [14] A. Hanel and C. Carlberg, "Vitamin D and evolution: Pharmacologic implications," *Biochemical pharmacology*, vol. 173, p. 113595, 2020.
- [15] D. Bikle and S. Christakos, "New aspects of vitamin D metabolism and action—addressing the skin as source and target," *Nature Reviews Endocrinology*, pp. 1-19, 2020.
- [16] C. Carlberg and A. Muñoz, "An update on vitamin D signaling and cancer," in *Seminars in cancer biology*, 2020.
- [17] S. H. Khazaal, K. F. Al-Azawi, H. A. Eassa, A. H. Khasraghi, W. R. Alfatlawi, and A. M. Al-Gebori, "Study the level of some heavy metals in water of Lake Habbaniyah in Al-Anbar-Iraq," *Energy Procedia*, vol. 157, pp. 68-74, 2019.
- [18] R. Bouillon, F. Schuit, L. Antonio, and F. Rastinejad, "Vitamin D binding protein: a historic overview," *Frontiers in endocrinology*, vol. 10, p. 910, 2020.
- [19] D. D. Bikle, "Vitamin D: Newer concepts of its metabolism and function at the basic and clinical level," *Journal of the Endocrine Society*, vol. 4, p. bvz038, 2020.
- [20] S. A. C. o. Nutrition, "SACN vitamin D and health report," 2016.
- [21] K.-H. Li, Y.-T. Liu, Y.-W. Yang, Y.-L. Lin, M.-L. Hung, and I.-C. Lin, "A positive correlation between blood glucose level and bone mineral density in Taiwan," *Archives of osteoporosis*, vol. 13, pp. 1-7, 2018.
- [22] J. A. Alvarez and A. Ashraf, "Role of vitamin D in insulin secretion and insulin sensitivity for glucose homeostasis," *International journal of endocrinology*, vol. 2010, 2010.
- [23] G. Jean, J. C. Souberbielle, and C. Chazot, "Vitamin D in chronic kidney disease and dialysis patients," *Nutrients*, vol. 9, p. 328, 2017.
- [24] M.-X. Ji and Q. Yu, "Primary osteoporosis in postmenopausal women," *Chronic diseases and translational medicine*, vol. 1, p. 9, 2015.
- [25] M. Alhumaidi, A. Adnan, and M. Dewish, "Vitamin D deficiency in patients with type-2 diabetes mellitus in southern region of Saudi Arabia," *Maedica*, vol. 8, p. 231, 2013.
- [26] Z. A. Ghareeb, H. A.-H. AlKhafaji, and M. K. A. Al-Saedi, "The Effect of LRP-1 Gene and Mir-205 on Cardiovascular Disease in Iraqi Patients with Familial Hypercholesterolemia," *Journal of Applied Sciences and Nanotechnology*, vol. 1, pp. 24-31, 2021.
- [27] R. Hidayat, S. Setiati, and P. Soewondo, "The association between vitamin D deficiency and type 2 diabetes mellitus in elderly patients," *Age*, vol. 52, p. 66.7, 2010.
- [28] E. D. Salman and H. S. Ahmed, "Bone mineral density an vitamin D status among postmenopausal iraqi women," *plant archives*, vol. 20, pp. 4613-4620, 2020 2020.
- [29] M. A. Najm, W. R. Alfatlawi, R. O. Saleh, and S. M. K. Al Taie, "Evaluation of Antioxidant (GSH, CAT, SOD) and MDA in Iraqi Women with Breast Cancer," *Journal of Global Pharma Technology*, vol.11, pp107-110, 2009.
- [30] M. A. Bayani, R. Akbari, B. Banasaz, and F. Saeedi, "Status of Vitamin-D in diabetic patients," *Caspian journal of internal medicine*, vol. 5, p. 40, 2014.

- [31] N. Suganthan, T. Kumanan, V. Kesavan, M. Aravinthan, and N. Rajeshkannan, "Vitamin D status among postmenopausal osteoporotic women: a hospital based cross-sectional study from Northern Sri Lanka," *BMC Nutrition*, vol. 6, 2020.
- [32] H. A. Bischoff-Ferrari, T. Dietrich, E. J. Orav, and B. Dawson-Hughes, "Positive association between 25-hydroxy vitamin D levels and bone mineral density: a population-based study of younger and older adults," *The American journal of medicine*, vol. 116, pp. 634-639, 2004.
- [33] R. Jorde, "The role of vitamin D binding protein, total and free 25-hydroxyvitamin D in diabetes," *Frontiers in endocrinology*, vol. 10, p. 79, 2019.
- [34] J. Sun, "Dietary vitamin D, vitamin D receptor, and microbiome," *Current opinion in clinical nutrition and metabolic care*, vol. 21, p. 471, 2018.
- [35] A. N. John and F.-X. Jiang, "An overview of type 2 diabetes and importance of vitamin D3-vitamin D receptor interaction in pancreatic β -cells," *Journal of Diabetes and its Complications*, vol. 32, pp. 429-443, 2018.
- [36] P. R. Ebeling and J. A. Eisman, "Vitamin D and osteoporosis," in *Vitamin D*, D. Feldman, Ed., fourth ed: Elsevier, 2018, pp. 203-220.
- [37] W. H., Y. Z., W. Z., G. Z., J. W., J. X., *et al.*, "Bone mineral density and bone metabolism in postmenopausal women with type 2 diabetes in a Chinese community: a cross-sectional study," 2020.
- [38] I. A., A. N. Demirer, N. B. Tutuncu, and M. E. Ertorer, "Prevalence of osteoporosis and factors affecting bone mineral density among postmenopausal Turkish women with type 2 diabetes," *Journal of Diabetes and its Complications*, vol. 23, pp. 12-17, 2009.
- [39] I. R., M. R., V. Z., and J. Š., "Prevalence and risk factors of osteoporosis in postmenopausal women with type 2 diabetes mellitus," *Central European journal of public health*, vol. 25, pp. 3-10, 2017.
- [40] A. B. Roomi, R. M. AL-Salih, and S. A. Ali, "The Effect Insulin Therapy and Metformin on Osteoporosis in Diabetic Post-Menopausal Iraqi Women," *Indian Journal of Public Health*, vol. 10, p. 1479, 2019.
- [41] I. H., B. M., V. C., D. P., and D. B., "Increased bone mineral density in postmenopausal women with type 2 diabetes mellitus," *Annals of Saudi medicine*, vol. 28, pp. 102-104, 2008.
- [42] V. S., M. G., S. K., S. L., K. M., A. N. N., *et al.*, "Multifactorial effects of hyperglycaemia, hyperinsulinemia and inflammation on bone remodelling in type 2 diabetes mellitus," *Cytokine & growth factor reviews*, vol. 55, pp. 109-118, 2020.
- [43] L. Z., X. S., J. Y., Y. X., and S. Y., "Metformin alleviates hyperglycemia-induced apoptosis and differentiation suppression in osteoblasts through inhibiting the TLR4 signaling pathway," *Life sciences*, vol. 216, pp. 29-38, 2019.
- [44] S. A. Paschou, A. D. Dede, P. G. Anagnostis, A. Vryonidou, D. Morganstein, and D. G. Goulis, "Type 2 diabetes and osteoporosis: a guide to optimal management," *The Journal of Clinical Endocrinology & Metabolism*, vol. 102, pp. 3621-3634, 2017.
- [45] R. E. and P. S., "Use of bone turnover markers in postmenopausal osteoporosis," *The lancet Diabetes & endocrinology*, vol. 5, pp. 908-923, 2017.
- [46] O. Akin, K. Göl, M. Aktürk, and S. Erkaya, "Evaluation of bone turnover in postmenopausal patients with type 2 diabetes mellitus using biochemical markers and bone mineral density measurements," *Gynecological endocrinology*, vol. 17, pp. 19-29, 2003.
- [47] A. Josheghanian, E. Akbari-hamed, E. Khanlarzadeh, M. h. Gholami, and S. Nikzad, "Treatment Outcomes and Survival of Patients with Gastric Cancer in Hamadan, Iran: A Retrospective Study," *Journal of Applied Sciences and Nanotechnology*, vol. 1, pp. 16-26, 2021.
- [48] M. Wakasugi, R. Wakao, M. Tawata, N. Gan, K. Koizumi, and T. Onaya, "Bone mineral density measured by dual energy x-ray absorptiometry in patients with non-insulin-dependent diabetes mellitus," *Bone*, vol. 14, pp. 29-33, 1993.
- [49] N. Younus, M. Altaee, and Z. A.-M. Sharba, "Correlation of MicroRNAs-122a Gene Expression with Diabetic for Iraqi Patients," *Journal of Applied Sciences and Nanotechnology*, vol. 1, pp. 64-72, 2021.

- [50] V. R. Jagtap, J. V. Ganu, and N. S. Nagane, "BMD and serum intact osteocalcin in postmenopausal osteoporosis women," *Indian Journal of Clinical Biochemistry*, vol. 26, pp. 70-73, 2011.
- [51] F. J. Al-Tu'ma and L. M. Z. Yosuf, "Vitamin D deficiency and hypertension in type 2 diabetic Iraqi patients," *J Contemp Med Sci*, vol. 1, pp. 17-20, 2015.
- [52] G. B. Marchand, A.-M. Carreau, S. J. Weisnagel, J. Bergeron, F. Labrie, S. Lemieux, *et al.*, "Increased body fat mass explains the positive association between circulating estradiol and insulin resistance in postmenopausal women," *American Journal of Physiology-Endocrinology and Metabolism*, vol. 314, pp. E448-E456, 2018.